ClinicalTrials.gg
CompletedNCT05856331ELEVAATEUpdated Aug 11, 2025

Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

A Phase 2 interventional study of SAR447537 and Zemaira in Alpha 1-Antitrypsin Deficiency and Emphysema, sponsored by Sanofi. Completed at 65 sites in 8 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States — 17 open to participants now, 22 under way, 5 of them phase 3. alpha 1-Antitrypsin Deficiency · United States.

Enrollment
11th of 55
99 · median 30
Started
2023
with 4 others
Phase 2
20 of 81
none open now
Registered
68th of 81
by date

Among the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, this one is the 11th largest by enrollment of the 55 interventional ones that give a count, is one of 5 that started in 2023, is one of 20 in phase 2, and was the 68th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

17 of the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, or all of them as a file.
02

Study summary

Phase 2 study to compare SAR447537 (INBRX-101) to plasma derived A1PI therapy in adults with AATD emphysema

Read the detailed description

This is a Phase 2, Double-Blind, Randomized, Active-Control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of SAR447537 (INBRX-101) Compared to Plasma-Derived Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema.

03

Conditions studied

  • Alpha 1-Antitrypsin Deficiency
  • Emphysema

Keywords

  • AATD
  • Alpha 1-Antitrypsin Deficiency
  • Emphysema
  • SAR447537
  • INBRX-101
  • A1PI
  • AAT
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females 18-80 years of age, inclusive, at the time of screening
  2. Diagnosis of AATD
  3. Evidence of emphysema secondary to AATD
  4. of ≥ 30% and ≤ 80% predicted at screening
  5. Current non-smoking status.

Exclusion criteria

Exclusion Criteria:

  1. Receipt of A1PI augmentation therapy within 5 weeks prior to the first dose of study drug
  2. Known or suspected allergy to components of SAR447537 (INBRX-101), A1PI or human IgG
  3. Known selective or severe Immunoglobulin A (IgA) deficiency
  4. Known or suspected diagnosis of type 1 diabetes or diagnosed with uncontrolled type 2 diabetes
  5. Received IV immunoglobulins, monoclonal antibodies and/or other biologic therapies within 30 days
  6. On waiting list for lung or liver transplant
  7. Acute respiratory tract infection or exacerbation within 4 weeks prior to or during screening
  8. Evidence of decompensated cirrhosis
  9. Active cancers or has a history of within 5 years prior to screening
  10. History of unstable cor pulmonale
  11. congestive heart failure
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    SAR447537 (INBRX-101) Q3W

    IV every 3-weeks (Q3W) and placebo (normal saline)

    Drug: SAR447537

  • Experimental
    SAR447537 (INBRX-101) Q4W

    IV every 4-weeks (Q4W) and placebo (normal saline)

    Drug: SAR447537

  • Active comparator
    Zemaira (A1PI)

    60 mg/kg IV once weekly (QW) and placebo (normal saline)

    Drug: Zemaira

Interventions

  • DrugSAR447537

    A1PI, Recombinant, Bivalent Fc Fusion Protein

  • Alpha1-Proteinase Inhibitor (Human)

    Also known as: Respreeza

06

What researchers measure

Primary outcomes

  1. Serum functional AAT (fAAT) levels at steady-state

    To assess the mean change in average fAAT concentration as measured by anti-neutrophil elastase capacity \[ANEC\] from baseline to average serum trough fAAT concentration at steady-state (Ctrough,ss) in participants treated with SAR447537 compared to A1PI

    Time frame: 32 Weeks

Secondary outcomes

  1. fAAT Concentration changes

    Mean change in serum fAAT concentration from baseline to fAAT average concentration at steady-state (Cavg, ss) in participants treated with SAR447537 compared to A1PI.

    Time frame: 32 Weeks

  2. Days with fAAT above the lower limit of the normal range

    Percentage of days with fAAT above the lower limit of the normal range during steady-state dosing in participants treated with SAR447537 compared to A1PI.

    Time frame: 32 weeks

  3. Incidence of TEAEs

    Incidence of all treatment-emergent adverse events (TEAEs), TEAEs ≥ Grade 3, serious adverse events (SAEs), TEAEs leading to IMP discontinuation, adverse events of special interest (AESI) (including infusion- related reactions).

    Time frame: 32 Weeks

  4. Anti-drug antibodies

    Frequency of anti-drug antibodies (ADA) against SAR447537 and endogenous AAT, as well as neutralizing ADA (NAb) against SAR447537 and endogenous AAT.

    Time frame: 32 Weeks

  5. Population Pharmacokinetics: Clearance

    Modeling by means of appropriate software to characterize the pharmacokinetic profile of SAR447537 via estimation of the parameter clearance

    Time frame: 32 Weeks

  6. Population Pharmacokinetics: Volume of Distribution

    Modeling by means of appropriate software to characterize the pharmacokinetic profile of SAR447537 via estimation of the parameter volume of distribution

    Time frame: 32 Weeks

  7. Covariate Analysis: Biometric Values: Weight

    Assessment of the impact of participant's weight \[in kg\] on the pharmacokinetic profile of SAR447537

    Time frame: 32 Weeks

  8. Covariate Analysis: Biometric Values: Height

    Assessment of the impact of participant's height \[in cm\] on the pharmacokinetic profile of SAR447537

    Time frame: 32 Weeks

  9. Covariate Analysis: Biometric Values: Age

    Assessment of the impact of participant's age \[in years\] on the pharmacokinetic profile of SAR447537

    Time frame: 32 Weeks

  10. Covariate Analysis: Biometric Values: Sex

    Assessment of the impact of participant's sex \[male or female\] on the pharmacokinetic profile of SAR447537

    Time frame: 32 Weeks

07

Study locations

65 sites
  • University of Alabama at Birmingham- Site Number : 105
    Birmingham, Alabama 35233-2110, United States
  • University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • St Joseph's Hospital and Medical Center- Site Number : 126
    Phoenix, Arizona 85013-4220, United States
  • St Joseph's Hospital and Medical Center
    Phoenix, Arizona 85013-4220, United States
  • David Geffen School of Medicine- Site Number : 124
    Los Angeles, California 90095-3075, United States
  • David Geffen School of Medicine
    Los Angeles, California 90095, United States
  • UC Davis Comprehensive Cancer Center- Site Number : 110
    Sacramento, California 95817, United States
  • UC Davis Medical Center
    Sacramento, California 95817, United States
  • National Jewish Medical and Research Center- Site Number : 123
    Denver, Colorado 80206-2761, United States
  • National Jewish Medical and Research Center
    Denver, Colorado 80206, United States
  • Western Connecticut Medical Group
    Danbury, Connecticut 06810, United States
  • University of Florida College of Medicine- Site Number : 101
    Gainesville, Florida 32610, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Bruce W. Carter Miami VA Medical Center - NAVREF - PPDS- Site Number : 114
    Miami, Florida 33125-1624, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Pulmonary and Sleep of Tampa Bay- Site Number : 115
    Tampa, Florida 33607-6316, United States
  • Pulmonary and Sleep of Tampa Bay
    Tampa, Florida 33607, United States
  • Loyola University Medical Center- Site Number : 112
    Maywood, Illinois 60153, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Indiana University
    Indianapolis, Indiana 46202-5128, United States
  • M Health Fairview Clinics and Surgery Center - Minneapolis- Site Number : 125
    Minneapolis, Minnesota 55455-4800, United States
  • M Health Fairview Clinics and Surgery Center - Minneapolis
    Minneapolis, Minnesota 55455-4800, United States
  • Hannibal Regional Healthcare System-HRMG-Hannibal- Site Number : 111
    Hannibal, Missouri 63401-6890, United States
  • Hannibal Clinic
    Hannibal, Missouri 63401, United States
  • Columbia University Irving Medical Center- Site Number : 104
    New York, New York 10032, United States
  • Oregon Health and Science University- Site Number : 117
    Portland, Oregon 97239, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Clinical Research Associates Of Central PA , LLC- Site Number : 128
    DuBois, Pennsylvania 15801-2277, United States
  • Clinical Research Associates Of Central PA , LLC
    DuBois, Pennsylvania 15801-2277, United States
  • Penn State Health Milton S. Hershey Medical Center- Site Number : 122
    Hershey, Pennsylvania 17033-2360, United States
  • Penn State Health Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Temple University Hospital- Site Number : 130
    Philadelphia, Pennsylvania 19140, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Velocity Clinical Research - Spartanburg - PPDS- Site Number : 120
    Spartanburg, South Carolina 29303-4225, United States
  • Velocity Clinical Research - Spartanburg - PPDS
    Spartanburg, South Carolina 29303, United States
  • Houston Methodist Hospital- Site Number : 113
    Houston, Texas 77030, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • University of Utah Health
    Salt Lake City, Utah 84108, United States
  • University of Utah Health Care- Site Number : 106
    Salt Lake City, Utah 84132-0001, United States
  • Donna McIntyre
    Brisbane, Queensland 2650, Australia
  • Queensland Centre for Pulmonary Transplantation
    Chermside, Queensland, Australia
  • Royal Adelaide Hospital
    North Adelaide, South Australia 5065, Australia
  • Eastern Health Clinical School
    Box Hill, Victoria 3128, Australia
  • Investigational Site Number : 203
    Fitzroy, Victoria 3065, Australia
  • St Vincent Hospital Melbourne
    Fitzroy, Victoria, Australia
  • Frankston Hospital
    Frankston, Victoria 3199, Australia
  • Institute for Respiratory Health
    Nedlands, Western Australia 6009, Australia
  • Investigational Site Number : 206
    Nedlands, Western Australia 6009, Australia
  • Investigational Site Number : 201
    Adelaide, 5000, Australia
  • Investigational Site Number : 202
    Chermside, 4032, Australia
  • Investigational Site Number : 701
    Hellerup, 2900, Denmark
  • Investigational Site Number : 702
    Vejle, 7100, Denmark
  • NZRSI
    Greenlane, Auckland 1051, New Zealand
  • Investigational Site Number : 403
    Auckland, 1051, New Zealand
  • Investigational Site Number : 404
    Wellington, 6021, New Zealand
  • P3 Research
    Wellington, 6021, New Zealand
  • Investigational Site Number : 801
    Warsaw, Masovian Voivodeship 01-138, Poland
  • Investigational Site Number : 802
    Krakow, 30-688, Poland
  • Investigational Site Number : 901
    Santander, Cantabria 39008, Spain
  • Investigational Site Number : 903
    Santiago de Compostela, La Coruña 15706, Spain
  • Investigational Site Number : 601
    Gothenburg, 413 46, Sweden
  • Ninewells Hospital - PPDS
    Dundee, Angus DD1 9SY, United Kingdom
  • Investigational Site Number : 306
    Wythenshawe, Cheshire West And Chester M23 9QZ, United Kingdom
  • Medicines Evaluation Unit
    Manchester, Cheshire M23 9QZ, United Kingdom
  • Investigational Site Number : 302
    Birmingham, Warwickshire B15 2WB, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Aug 2025, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2023
First posted
May 12, 2023
StartActual
Oct 12, 2023
Primary completionActual
Aug 6, 2025
CompletionActual
Aug 6, 2025
Last update
Aug 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05856331
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 12, 2023
Start date
Oct 12, 2023
Primary completion
Aug 6, 2025
Completion
Aug 6, 2025
Last update
Aug 11, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion